{"id":"f4532577-0cf3-40d6-9a60-e7c7933db88b","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape?condition=Disease+area+%E2%80%94+e.g.+%22Parkinson+Disease%22+%7C+%22Breast+Cancer%22+%7C+%22NASH%22+%7C+%22Heart+Failure%22+%7C+%22Schizophrenia%22&depth=standard+%7C+deep+%28default%3A+standard%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29","method":"GET","fingerprint":"41e7565e564faed4a57788da6fd85122d6bc447b1ec287329c058e133a7218cf","name":"ClinicalIntelPulse","description":null,"category":"other","docs_url":null,"advertised_price_usd":"0.350000","asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","scheme":"exact","networks":["eip155:8453","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","eip155:137","eip155:42161","eip155:480","eip155:143","eip155:196","eip155:999","algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","xrpl:0","eip155:56"],"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","input_schema":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"depth":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output_schema":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}},"schema_completeness":0,"status":"live","first_seen_at":"2026-08-23 12:44:23.408592+00","last_seen_at":"2026-08-23 16:50:29.972+00","last_success_at":"2026-10-15 11:53:51.295+00","dead_since":null,"probe_backoff_tier":0,"next_probe_at":"2026-10-15 11:58:51.295+00","search_tsv":"'clinicalintelpuls':1","catalog_number":"9460","x402_version":2,"resource_url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape","resource_description":"Competitive drug pipeline landscape for any disease — full Phase 2/3 trial map, mechanism-of-action coverage, approved drugs, PDUFA calendar, M&A activity, opportunity gaps and investment thesis. Worldwide. For biotech and pharma intelligence agents.","bazaar_extension":{"info":{"input":{"type":"http","method":"GET","queryParams":{"lang":"en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)","depth":"standard | deep (default: standard)","condition":"Disease area — e.g. \"Parkinson Disease\" | \"Breast Cancer\" | \"NASH\" | \"Heart Failure\" | \"Schizophrenia\""}},"output":{"type":"json","errors":{"400":{"example":{"error":"invalid request"},"description":"Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints."},"402":{"description":"Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free."},"500":{"example":{"error":"upstream_failed"},"description":"Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit."}},"example":{"deal_activity":"Highly active M&A space. AstraZeneca acquired Eccogene NASH program ($185M). Roche/Genentech building liver portfolio. Novo Nordisk GLP-1 dominance creating competitive panic.","query_summary":{"as_of":"2026-06-07","depth":"standard","condition":"NASH (Nonalcoholic Steatohepatitis)"},"approved_drugs":[{"name":"Resmetirom (Rezdiffra)","sponsor":"Madrigal Pharmaceuticals","approved":"2024-03","mechanism":"THR-β agonist","indication":"NASH with moderate-to-advanced fibrosis"}],"pdufa_calendar":[{"drug":"Lanifibranor","sponsor":"Inventiva","mechanism":"Pan-PPAR","pdufa_estimate":"2026-Q1","priority_review":false}],"investment_thesis":"NASH market projected $18-25B by 2030. Resmetirom first approval sets pricing precedent. GLP-1 combination therapy is the likely future standard of care.","opportunity_score":{"max":100,"note":"Validated market with first approval. GLP-1 expansion threatening narrow competitors.","score":78,"rating":"High Value"},"pipeline_overview":{"phase2_count":48,"phase3_count":19,"total_active":67,"approved_drugs":2,"approval_recent_12m":1},"top_phase3_assets":[{"drug":"Semaglutide 2.4mg","nctId":"NCT04858633","sponsor":"Novo Nordisk","mechanism":"GLP-1 RA","completion":"2025-Q4","significance":"Blockbuster potential — NASH + obesity combined label"}],"mechanism_landscape":{"crowded":["FXR agonists (8 Phase 2/3)","ACC inhibitors (6)","FGF21 analogs (5)"],"emerging":["Pan-PPAR agonists","GLP-1/GIP combinations (semaglutide expanding)"],"opportunity_gaps":["Cirrhosis reversal agents","Pediatric NAFLD","Combination sequential therapy protocols"]},"key_readouts_next_18m":["NASH-RESOLVE (semaglutide histology 2025)","MAESTRO-NASH (lanifibranor 2025)","ATLAS trial (aldafermin 2026)"]}}},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"depth":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}}},"accepted_requirements":[{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":300},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"350000"},{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"GatewayWalletBatched","version":"1","verifyingContract":"0x77777777dcc4d5a8b6e418fd04d8997ef11000ee"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":604900},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"350000"},{"raw":{"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","extra":{"feePayer":"Hc3sdEAsCGQcpgfivywog9uwtk8gUBUZgsxdME1EJy88"},"payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","amount":"350000","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","maxTimeoutSeconds":300},"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","amountAtomic":"350000"},{"raw":{"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:137","maxTimeoutSeconds":300},"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:137","amountAtomic":"350000"},{"raw":{"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:42161","maxTimeoutSeconds":300},"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:42161","amountAtomic":"350000"},{"raw":{"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:480","maxTimeoutSeconds":300},"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:480","amountAtomic":"350000"},{"raw":{"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:143","maxTimeoutSeconds":300},"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:143","amountAtomic":"350000"},{"raw":{"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","extra":{"name":"USD₮0","version":"1"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:196","maxTimeoutSeconds":300},"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:196","amountAtomic":"350000"},{"raw":{"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:999","maxTimeoutSeconds":300},"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:999","amountAtomic":"350000"},{"raw":{"asset":"31566704","extra":{"feePayer":"ZMFK2OI7ZBD2U27ISERZC4S6LKM6WMFJPZQ4MYNJDZ2VNBNMBA67RA22AA"},"payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","amount":"350000","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","maxTimeoutSeconds":300},"asset":"31566704","payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","amountAtomic":"350000"},{"raw":{"asset":"XRP","extra":{"invoiceId":"F984A1D2F03240E6B0A5C066BB7D4981","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"350000","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"XRP","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"350000"},{"raw":{"asset":"524C555344000000000000000000000000000000","extra":{"issuer":"rMxCKbEDwqr76QuheSUMdEGf4B9xJ8m5De","invoiceId":"CFF675A8CF28424C97F07BDD49C6A9F5","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"0.35","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"524C555344000000000000000000000000000000","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"0.35"},{"raw":{"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","extra":{"name":"World Liberty Financial USD","version":"1","signerAddress":"0x34F7a661160780Ce1346e6D7B96D2bE244590899","assetTransferMethod":"eip3009"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000000000000000","scheme":"exact","network":"eip155:56","maxTimeoutSeconds":300},"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:56","amountAtomic":"350000000000000000"}],"bazaar_compatible":true,"bazaar_validated_at":"2026-10-15 11:53:51.295+00","bazaar_validation_error":null,"window":"24h","probes_n":12,"handshake_uptime":1,"settle_success_rate":0,"valid_result_rate":null,"latency_p50":714,"latency_p90":4322,"price_drift_pct":0,"score":0.7011,"computed_at":"2026-10-15 11:54:10.368+00","source_metadata":[{"raw":{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape?condition=Disease+area+%E2%80%94+e.g.+%22Parkinson+Disease%22+%7C+%22Breast+Cancer%22+%7C+%22NASH%22+%7C+%22Heart+Failure%22+%7C+%22Schizophrenia%22&depth=standard+%7C+deep+%28default%3A+standard%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29","name":"ClinicalIntelPulse","method":"GET","source":"bazaar:api.cdp.coinbase.com","fingerprint":"41e7565e564faed4a57788da6fd85122d6bc447b1ec287329c058e133a7218cf","advertisedPriceUsd":0.35},"source_id":1,"external_id":null}],"live_endpoint_metadata":{"x402_version":2,"resource_url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape","resource_description":"Competitive drug pipeline landscape for any disease — full Phase 2/3 trial map, mechanism-of-action coverage, approved drugs, PDUFA calendar, M&A activity, opportunity gaps and investment thesis. Worldwide. For biotech and pharma intelligence agents.","bazaar_extension":{"info":{"input":{"type":"http","method":"GET","queryParams":{"lang":"en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)","depth":"standard | deep (default: standard)","condition":"Disease area — e.g. \"Parkinson Disease\" | \"Breast Cancer\" | \"NASH\" | \"Heart Failure\" | \"Schizophrenia\""}},"output":{"type":"json","errors":{"400":{"example":{"error":"invalid request"},"description":"Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints."},"402":{"description":"Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free."},"500":{"example":{"error":"upstream_failed"},"description":"Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit."}},"example":{"deal_activity":"Highly active M&A space. AstraZeneca acquired Eccogene NASH program ($185M). Roche/Genentech building liver portfolio. Novo Nordisk GLP-1 dominance creating competitive panic.","query_summary":{"as_of":"2026-06-07","depth":"standard","condition":"NASH (Nonalcoholic Steatohepatitis)"},"approved_drugs":[{"name":"Resmetirom (Rezdiffra)","sponsor":"Madrigal Pharmaceuticals","approved":"2024-03","mechanism":"THR-β agonist","indication":"NASH with moderate-to-advanced fibrosis"}],"pdufa_calendar":[{"drug":"Lanifibranor","sponsor":"Inventiva","mechanism":"Pan-PPAR","pdufa_estimate":"2026-Q1","priority_review":false}],"investment_thesis":"NASH market projected $18-25B by 2030. Resmetirom first approval sets pricing precedent. GLP-1 combination therapy is the likely future standard of care.","opportunity_score":{"max":100,"note":"Validated market with first approval. GLP-1 expansion threatening narrow competitors.","score":78,"rating":"High Value"},"pipeline_overview":{"phase2_count":48,"phase3_count":19,"total_active":67,"approved_drugs":2,"approval_recent_12m":1},"top_phase3_assets":[{"drug":"Semaglutide 2.4mg","nctId":"NCT04858633","sponsor":"Novo Nordisk","mechanism":"GLP-1 RA","completion":"2025-Q4","significance":"Blockbuster potential — NASH + obesity combined label"}],"mechanism_landscape":{"crowded":["FXR agonists (8 Phase 2/3)","ACC inhibitors (6)","FGF21 analogs (5)"],"emerging":["Pan-PPAR agonists","GLP-1/GIP combinations (semaglutide expanding)"],"opportunity_gaps":["Cirrhosis reversal agents","Pediatric NAFLD","Combination sequential therapy protocols"]},"key_readouts_next_18m":["NASH-RESOLVE (semaglutide histology 2025)","MAESTRO-NASH (lanifibranor 2025)","ATLAS trial (aldafermin 2026)"]}}},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"depth":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}}},"accepted_requirements":[{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":300},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"350000"},{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"GatewayWalletBatched","version":"1","verifyingContract":"0x77777777dcc4d5a8b6e418fd04d8997ef11000ee"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":604900},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"350000"},{"raw":{"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","extra":{"feePayer":"Hc3sdEAsCGQcpgfivywog9uwtk8gUBUZgsxdME1EJy88"},"payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","amount":"350000","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","maxTimeoutSeconds":300},"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","amountAtomic":"350000"},{"raw":{"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:137","maxTimeoutSeconds":300},"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:137","amountAtomic":"350000"},{"raw":{"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:42161","maxTimeoutSeconds":300},"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:42161","amountAtomic":"350000"},{"raw":{"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:480","maxTimeoutSeconds":300},"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:480","amountAtomic":"350000"},{"raw":{"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:143","maxTimeoutSeconds":300},"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:143","amountAtomic":"350000"},{"raw":{"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","extra":{"name":"USD₮0","version":"1"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:196","maxTimeoutSeconds":300},"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:196","amountAtomic":"350000"},{"raw":{"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:999","maxTimeoutSeconds":300},"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:999","amountAtomic":"350000"},{"raw":{"asset":"31566704","extra":{"feePayer":"ZMFK2OI7ZBD2U27ISERZC4S6LKM6WMFJPZQ4MYNJDZ2VNBNMBA67RA22AA"},"payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","amount":"350000","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","maxTimeoutSeconds":300},"asset":"31566704","payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","amountAtomic":"350000"},{"raw":{"asset":"XRP","extra":{"invoiceId":"F984A1D2F03240E6B0A5C066BB7D4981","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"350000","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"XRP","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"350000"},{"raw":{"asset":"524C555344000000000000000000000000000000","extra":{"issuer":"rMxCKbEDwqr76QuheSUMdEGf4B9xJ8m5De","invoiceId":"CFF675A8CF28424C97F07BDD49C6A9F5","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"0.35","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"524C555344000000000000000000000000000000","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"0.35"},{"raw":{"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","extra":{"name":"World Liberty Financial USD","version":"1","signerAddress":"0x34F7a661160780Ce1346e6D7B96D2bE244590899","assetTransferMethod":"eip3009"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000000000000000","scheme":"exact","network":"eip155:56","maxTimeoutSeconds":300},"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:56","amountAtomic":"350000000000000000"}],"bazaar_compatible":true,"bazaar_validated_at":"2026-10-15 11:53:51.295+00","bazaar_validation_error":null},"sonar_metrics":{"score":0.7011,"uptime":1,"paid_success_rate":0,"valid_result_rate":null,"latency_p50":714,"latency_p90":4322,"price_drift_pct":0},"cdp_indexed":false,"confidence":"medium"}